Funded with Support from

This lecture from Pediatric Ophthalmology 2017 presents arguments for keratoprosthesis in children, including some immediate benefits and a successful case.

This lecture from Pediatric Ophthalmology 2017 discusses the various classifications of intermittent exotropia and testing strategies that impact the size, classification, and/or treatment of the deviation.

In this interview from AAO 2017, 2 members of an expert panel—Drs. Alison Skalet and Patricia Chévez-Barrios—discuss the take-home points from the consensus statement.

Retinoblastoma (Rb) is a primary intraocular cancer that develops in the eyes of young children most often under the age of 5 years.Access to the acueous humor AH of eyes with active Rb has enabled the first-ever genetic analyses of Rb tumors in situ (ie, without enucleation). This is the first time that retinoblastoma tumor DNA has been available from eyes before they were enucleated. [Please also see the interview with Dr. Berry at https://www.aao.org/interview/aqueous-humor-biopsy-retinoblastoma.]

In this interview from AAO 2017, Dr. Jesse Berry discusses her groundbreaking study showing that genetic analysis of a retinoblastoma tumor can be performed using a sample of aqueous humor.

This lecture presents the case for using propranolol as a first line of treatment for infantile hemangioma.

This report by a multidisciplinary task force is the first consensus statement on clinical care guidelines for pediatric orbital-periorbital plexiform neurofibromas (OPPNs).

This study validates that prenatal molecular testing enables the child to be delivered early, but full term, resulting in fewer and smaller tumors present at birth and a better chance at retaining vision.

In this video from ARVO 2016, Dr. Anthony B. Daniels discusses his work on intra-arterial chemotherapy for group D retinoblastoma.